| Brief Title | Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer |
|---|---|
| Official Title | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy |
| Principal Investigator | Nanda, Rita |
| Brief Summary | This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. |
| Gender | All |
| Ages | 18 Years |
| Enrollment | 1000 |
| Accepts Healthy Volunteers | No |
| Lead Sponsor | National Cancer Institute (NCI)NIH |
| Collaborator | |
| Study Design | |
| Study Phase | Phase 3 |
| Study Type | Interventional |
| Contact Name | Gary E. Goodman |
| Contact Phone | 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) |
| Condition | Estrogen Receptor Negative |